Amgen to buy biotech startup TeneoBio
Amgen announced July 27 that it plans to buy a privately held Bay Area biotech company called TeneoBio in an all-cash deal worth as much as $2.5 billion. The deal is expected to close in the second half of this year and calls for Amgen to pay $900 million up front for all outstanding shares Read More →
Read More →Takeda expansion is latest coup for Conejo Valley pharma industry
Takeda Pharmaceuticals, a Japanese company with major operations in the Conejo Valley, will expand its facility in Thousand Oaks, investing $126 million to build out the manufacturing operations to support new product lines. The Takeda team, alongside the mayor of Thousand Oaks, Claudia Bill-de la Peña, is scheduled to hold a groundbreaking ceremony for the Read More →
Read More →
Biotech’s movers and shakers gather for BioMedley
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Thousand Oaks biotech firm closes $140M funding round
Capsida Biotherapeutics, a biotechnology startup based in Thousand Oaks, announced April 29 that it is emerging from “stealth mode” with a $140 million funding round led by Westlake Village BioPartners and Versant Ventures. The Series A round includes $50 million from Westlake Village BioPartners, a venture capital firm in Thousand Oaks focused on biotech startups Read More →
Read More →Amgen to buy cancer treatment biotech firm for $1.9B
Thousand Oaks-based Amgen, one of the biggest biotech companies in the world, will get bigger with the $1.9 billion acquisition of Five Prime Therapeutics, a clinical-stage biotech company developing stomach cancer therapies. Amgen announced the acquisition March 4 and the deal is expected to close by the end of the second quarter of 2021. Under Read More →
Read More →MannKind stock dips on report of 2020 losses, but company touts fourth quarter comeback
MannKind Corp. struggled during 2020, but impressive financial results from its final quarter could be a sign of good things to come for the Westlake Village biotech company. MannKind, which develops drugs and treatments for those suffering from diabetes and pulmonary arterial hypertension, reported a net loss of $57.2 million in fiscal year 2020, up Read More →
Read More →‘Golden age of biotechnology’ comes to Conejo Valley
Westlake Village BioPartners has launched two new funds worth a total of $500 million, bringing the total raised by the firm to more than $820 million since it was founded in 2018.
Read More →
Sponsored content:
